RankAlpha logo
Back to Rankings

TGTX

TG TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
BRIUMVI's 64% year-over-year second-quarter U.S. sales growth and raised 2026 target support the commercial thesis; the October 21 company update adds seven-year disease-control data and a potential simpler initiation regimen.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.0.
What can break
Azer-cel data are initial Phase 1 evidence; efficacy, durability, and safety in progressive MS remain unproven.
Momentum
85
Value
58
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $62.00 · Bull $76.00 · Bear $38.00Analysis 2026-10-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-22 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $69.71
Why
Momentum85 · Δ7d -14.7
Value58 · Δ7d -0.2
Sentiment67 · Δ7d +1.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +1.0.

Contradictions & invalidation

  • • Azer-cel data are initial Phase 1 evidence; efficacy, durability, and safety in progressive MS remain unproven.
  • • BRIUMVI carries infusion-reaction, infection, hepatitis B reactivation, and PML warnings. Company clinical update
  • • The valuation depends heavily on sustained BRIUMVI uptake, while Phase 3 subcutaneous and early azer-cel outcomes remain uncertain.

Catalyst clock

2026-10-22

ENHANCE single-infusion dosing assessment

Lead driver: Sentiment · See AI snapshot
Momentum
85
8% active weight
Current posture
7d trendSoftening
Δ7d
-14.7
Δ21d
-12.4
Value
58
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.8
Sentiment
67
45% active weight
Current posture
7d trendImproving
Δ7d
+1.0
Δ21d
+2.6
Why this grade

Composite grade A. Momentum 85.4 / Value 57.7 / Sentiment 67.2

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-22. Scenario method

B+
Bull case
30%
Probability
Target price
$76.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$62.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$8.29B
Beta
1.85
Shares Out
153.07M
P/E (TTM)
10.8
P/S (TTM)
8.92
P/FCF (TTM) · Derived
473.93
Rev YoY
+70.3%
EPS YoY
-71.5%
Gross Margin
+82.4%
Op Margin
+17.1%
Net Debt
$111.74M
Current Ratio
4.27
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data